P = 0.016) and all-cause mortality (RRR: 44%, HR: 0.35
In summary, tirzepatide is the first dual receptor agonist that was recently approved for the treatment of T2D by the FDA
Mounjaro may be the better choice if: You need treatment now (retatrutide is not yet available) You prefer a medication with extensive real-world safety data Your BMI qualifies you for current GLP-1 prescriptions You have type 2 diabetes (Mounjaro has robust diabetes data) You are sensitive to GI side effects and want a well-established titration protocol Your weight loss goals are achievable with 15 to 22% body weight reduction You want insurance coverage options (available for some plans) Mounjaro is the proven, accessible, right-now option
However, current evidence is not sufficient to support combining these peptides in clinical practice, and their long-term safety and effectiveness have yet to be established through well-designed human studies
[5] GPX4 is a phospholipid hydroperoxidase that protects cells against membrane lipid peroxidation
Saline (0.9 percent NaCl) should be avoided because chloride competes for Cu(II) coordination and destabilizes the GHK-Cu chelate